Clinical Trial Update: Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002) [Phase 1]

View source ↗

Summary

This Phase 1 study reports safety, pharmacokinetics, and pharmacodynamics of MK-2248 in participants with hepatitis C, focusing on tolerability and how the drug…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• MK-2248

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED